2017年度 論文

1.         Amatya VJ, Kushitani K, Mawas AS, Miyata Y, Okada M, Kishimoto T, Inai K, Takeshima Y. : MUC4, a novel immunohistochemical marker identified by gene expression profiling, differentiates pleural sarcomatoid mesothelioma from lung sarcomatoid carcinoma. Mod Pathol. 2017 May;30(5):672-681.

2.         Kuraoka M, Amatya VJ, Kushitani K, Mawas AS, Miyata Y, Okada M, Kishimoto T, Inai K, Nishisaka T, Sueda T, Takeshima Y.:  Identification of DAB2 and Intelectin-1 as Novel Positive Immunohistochemical Markers of Epithelioid Mesothelioma by Transcriptome Microarray Analysis for its Differentiation From Pulmonary Adenocarcinoma. Am J Surg Pathol. 2017 Aug;41(8):1045-1052.

3.         Ito H, Nakayama H, Murakami S, Yokose T, Katayama K, Miyata Y, Okada M.: Does the histologic predominance of pathological stage IA lung adenocarcinoma influence the extent of resection? Gen Thorac Cardiovasc Surg.  2017 Sep;65(9):512-518.

4.         Akayama K, Miyata Y, Kawahara T, Okada M, Kaneko M, Okajima M, Ohdan H.: New noncontact sensor for detecting pulmonary tumors during video-assisted thoracic surgery. J Surg Res. 2017 Jun 15;214:62-68.

5.         Horimasu Y, Ishikawa N, Taniwaki M, Yamaguchi K, Hamai K, Iwamoto H, Ohshimo S, Hamada H, Hattori N, Okada M, Arihiro K, Ohtsuki Y, Kohno N.: Gene expression profiling of idiopathic interstitial pneumonias (IIPs): identification of potential diagnostic markers and therapeutic targets. BMC Med Genet. 2017 Aug 18;18(1):88.

6.         Endo S, Ikeda N, Kondo T, Nakajima J, Kondo H, Yokoi K, Chida M, Sato M, Toyooka S, Yoshida K, Okada Y, Sato Y, Okada M, Okumura M, Chihara K, Fukuchi E, Miyata H.: Model of lung cancer surgery risk derived from a Japanese nationwide web-based database of 78594 patients during 2014-2015. Eur J Cardiothorac Surg. 2017 Dec 1;52(6):1182-1189.

7.         Watanabe SI, Nakagawa K, Suzuki K, Takamochi K, Ito H, Okami J, Aokage K, Saji H, Yoshioka H, Zenke Y, Aoki T, Tsutani Y, Okada M.: Lung Cancer Surgical Study Group (LCSSG) of the Japan Clinical Oncology Group (JCOG). Neoadjuvant and adjuvant therapy for Stage III non-small cell lung cancer. Jpn J Clin Oncol. 2017 Dec 1;47(12):1112-1118.

8.         Hishida T, Saji H, Watanabe SI, Asamura H, Aokage K, Mizutani T, Wakabayashi M, Shibata T, Okada M.: Lung Cancer Surgical Study Group of the Japan Clinical Oncology Group (JCOG-LCSSG). A randomized Phase III trial of lobe-specific vs. systematic nodal dissection for clinical Stage I-II non-small cell lung cancer (JCOG1413). Jpn J Clin Oncol. 2018 Feb 1;48(2):190-194.

9.         Ito M, Miyata Y, Hirano S, Kimura S, Irisuna F, Ikeda K, Kushitani K, Tsutani Y, Ueda D, Tsubokawa N, Takeshima Y, Okada M.: Therapeutic strategies and genetic profile comparisons in small cell carcinoma and large cell neuroendocrine carcinoma of the lung using next-generation sequencing. Oncotarget. 2017 Nov 14;8(65):108936-108945.

10.     Mawas AS, Amatya VJ, Kushitani K, Kai Y, Miyata Y, Okada M, Takeshima Y.: MUC4 immunohistochemistry is useful in distinguishing epithelioid mesothelioma from adenocarcinoma and squamous cell carcinoma of the lung. Sci Rep. 2018 Jan 9;8(1):134.

11.     Amatya VJ, Kushitani K, Kai Y, Suzuki R, Miyata Y, Okada M, Takeshima Y.: Glypican-1 immunohistochemistry is a novel marker to differentiate epithelioid mesothelioma from lung adenocarcinoma. Mod Pathol. Mod Pathol. 2018;31(5):809-815.

12.     Karachaliou N, Chaib I, Cardona AF, Berenguer J, Bracht JWP, Yang J, Cai X, Wang Z, Hu C, Drozdowskyj A, Servat CC, Servat JC, Ito M, Attili I, Aldeguer E, Capitan AG, Rodriguez J, Rojas L, Viteri S, Molina-Vila MA, Ou SI, Okada M, Mok TS, Bivona TG, Ono M, Cui J, Cajal SRY, Cao P, Rosell R.: Common Co-activation of AXL and CDCP1 in EGFR-mutation-positive Non-smallcell Lung Cancer Associated With Poor Prognosis. EBioMedicine. 2018 Mar;29:112-127.

13.     Matsuura K, Itamoto T, Noma M, Ohara M, Akimoto E, Doi M, Nishisaka T, Arihiro K, Kadoya T, Okada M.: Significance of lung biopsy for the definitive diagnosis of lung nodules in breast cancer patients. Mol Clin Oncol. 2018 Feb;8(2):250-256.

14.     Kushitani K, Amatya VJ, Mawas AS, Suzuki R, Miyata Y, Okada M, Inai K, Kishimoto T, Takeshima Y.: Utility of Survivin, BAP1, and Ki-67 immunohistochemistry in distinguishing epithelioid mesothelioma from reactive mesothelial hyperplasia. Oncol Lett. 2018 Mar;15(3):3540-3547.

15.     Kim R, Kawai A, Wakisaka M, Funaoka Y, Ohtani S, Ito M, Kadoya T, Okada M: Differences in immune response to anesthetics used for day surgery versus hospitalization surgery for breast cancer patients. Clin Transl Med. 2017 .

16.     kimoto E, Kadoya T, Kajitani K, Emi A, Shigematsu H, Ohara M, Masumoto N, Okada M: Role of 18F-PET/CT in predicting prognosis of patients with breast cancer after neoadjuvant chemotherapy. Clin Breast Cancer, 2017 .

17.     Matsuura K, Itamoto T, Noma M, Ohara M, Akimoto E, Doi M, Nishisaka T, Arihiro K, Kadoya T, OkadaM: Significance of lung biopsy for the definitive diagnosis of lung nodules in breast cancer patients.Mol Clin Oncol.8:250-256, 2017.

18.     Hamai, Y., Hihara, J., Emi, M., Furukawa, T., Ibuki, Y., Yamakita, I., Kurokawa, T., Okada, M.: Effects of Neoadjuvant Chemoradiotherapy on Pathological TNM Stage and Their Prognostic Significance for Surgically-treated Esophageal Squamous Cell Carcinoma. Anticancer Res. 37: 5639-5646, 2017.

19.     Emi, M., Jun Hihara., Furukawa, T., Ibuki, Y., Okada, M.:Clinicopathologic Features of Submucosal Esophageal Squamous Cell Carcinoma. Ann Thorac Surg. 2017 Dec;104(6):1858-1864.

20.     Tsutani, Y., Mimura, T., Kai, Y., Ito, M., Misumi, K., Miyata, Y., Okada, M.: Outcomes after lobar versus sublobar resection for clinical stage I non-small cell lung cancer in patients with interstitial lung disease. J Thorac Cardiovasc Surg. Sep;154(3):1089-1096.

21.     Tsutani Y., Tsubokawa N., Ito M., Misumi K., Hanaki H., Miyata Y., Okada M.: Postoperative complications and prognosis after lobar resection versus sublobar resection in elderly patients with clinical Stage I non-small-cell lung cancer. Eur J Cardiothorac Surg. 2017 Sep 6.

22.     Sasada, S., Ushirozawa, N., Kobayashi, N., Fujiwara, Y., Tamura, K., Yamamoto, N.: Surveillance of protocol deviations in Japanese oncology registration trials: a single institute experience. Invest New Drugs 35: 392-396, 2017.

23.     Sasada, S., Kurihara, H., Kinoshita, T., Yoshida, M., Honda, N., Shimoi, T., Shimomura, A., Yunokawa, M., Yonemori, K., Shimizu, C., Hamada, A., Kanayama, Y., Watanabe, Y., Fujiwara, Y., Tamura, K.: 64Cu-DOTA-Trastuzumab PET imaging for HER2-specific primary lesions of breast cancer. Ann Oncol 28: 2028-2029, 2017.

24.     Sasada, S., Kurihara, H., Kinoshita, T., Yoshida, M., Honda, N., Shimoi, T., Shimomura, A., Yonemori, K., Shimizu, C., Hamada, A., Kanayama, Y., Watanabe, Y., Fujiwara, Y., Tamura, K.: Visualization of HER2-specific breast cancer intratumoral heterogeneity using 64Cu-DOTA-trastuzumab PET. Eur J Nucl Med Mol Imaging 44: 2146-2147, 2017.

25.     Iizumi. S., Shimoi. T., Nishikawa. T., Kitano. A., Sasada. S., Shimomura. A., Noguchi. E., Yunokawa. M., Yonemori. K., Shimizu. C., Fujiwara. Y., Tamura. K.: Prolonged Hypocalcemia Following a Single Dose of Denosumab for Diffuse Bone Metastasis of Gastric Cancer after Total Gastrectomy. Intern Med 56: 2879-2882, 2017.

26.     Song, H., Sasada, S., Kadoya, T., Okada, M., Arihiro, K., Xiao, X., Kikkawa, T.: Detectability of Breast Tumor by a Hand-held Impulse-Radar Detector: Performance Evaluation and Pilot Clinical Study. Sci Rep 7: 16353, 2017.

27.     Sasada, S., Yunokawa, M., Takehara, Y., Ishikawa, M., Ikeda, S., Kato, T., Tamura, K.: Baseline risk of recurrence in stage I-II endometrial carcinoma. J Gynecol Oncol 29: e9, 2018.

28.     Sasada, S., Shien, T., Iwata, H. Current status of postmastectomy radiation therapy in T1-2 breast cancer with limited positive lymph nodes in Japan: Japan Clinical Oncology Group Survey. Breast Cancer 2018 .

29.     Ibuki, Y., Hamai, Y., Hihara, J., Emi, M., Taomoto, J., Furukawa, T., Yamakita, I., Kurokawa, T., Okada, M.: Role of Postoperative C-Reactive Protein Levels in Predicting Prognosis After Surgical Treatment of Esophageal Cancer. World J Surg. 2017 Jun 24.

30.     Ibuki, Y., Tsutani, Y., Miyata, Y., Nakayama, H., Okumura, S., Yoshimura, M., Okada, M.: Preoperative predictors of distant recurrence in patients with clinical stage IA lung adenocarcinoma undergoing complete resection. Jpn J Clin Oncol. 47(2):157-163, 2017.

31.     Koi, Y1, Koga, C2, Akiyoshi, S3, Masuda, T2, Ijichi, H2, Nakamura, Y2, Ishida, M2,  Ohno, S3, Tokunaga, E2(1) Surgical Oncology, Division of Radiation Biology and Medicine, Graduate School of Biochemical & Health Sciences, Hiroshima University, Hiroshima, Japan, 2) Depertment of Breast Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan, 3) Breast Center, The Cancer Institute Hospital of the Japanese Foundation of Cancer Research, Tokyo, Japan): Impact of Visceral Metastasis on Efficacy of Fulvestrant in Patients with Hormone Receptor-positive Recurrent Breast Cancer. Anticancer Res. 2018 Mar;38(3):1579-1584.

32.     Handa Y1, Tsutani Y1, Tsubokawa N1, Misumi K1, Hanaki H1, Miyata Y1, Okada M1.(1) Department of Surgical Oncology, Hiroshima University, Hiroshima, Japan.):Clinical Prognosis of Superior Versus Basal Segment Stage I Non-Small Cell Lung Cancer Ann Thorac Surg. 104(6):1896-1901. 2017 Dec. Epub 2017 Oct 21.

33.     笹田伸介,栗原宏明,濱田哲暢,田村研治:分子イメージングの開発と臨床応用.日本臨牀75177-180,2017.

34.     乳房専用PET装置の臨床経験と将来展望.新医療4551-54,2018.

35.     Elmammoによる乳癌術前化学療法の効果判定~ESMO2017に参加して~.MEDICAL NOW8320-23,2018.